DRUG

Jefferies initiated coverage of Bright Minds Biosciences with a rating of Buy and set a new price target of $145.00

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences: EVENT:TD Cowen 46th Annual Health Care ConferenceDATE:Wednesday, March 4, 2026TIME:9:10am ETWEBCAST:https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/cy8oQuZ2XnJiLiEqXopBn7 EVENT: Leerink Partners 2026 Global Healthcare ConferenceDATE: Monday, March 9, 2026WEBCAST:No

SCHEDULE 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

SCHEDULE 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)

SCHEDULE 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945,000 common shares in the capital of the Company (the "Common Shares") at a price of US$90.00 per Common Share for gross proceeds of US$175,050,000 (the "Offering"). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 291,750 Common Shares at the public offering price, less underwriting discounts and commissions. All of the securities sold in this Offering were offered by Bright Minds. The Company intends to use the net proceeds

6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)

424B5 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)

6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") announces the pricing of its previously announced public offering of 1,945,000 common shares in the capital of the Company (the "Common Shares") at a price of $90.00 per Common Share for anticipated gross proceeds of $175,050,000 (the "Offering"). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 291,750 Common Shares at the public offering price, less underwriting discounts and commissions. All of the securities being sold in this Offering are being offered by Bright Minds. The closing

6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)

FWP - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

FWP - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

424B5 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)

6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") announces the launch of a public offering of common shares in the capital of the Company (the "Common Shares") and, in lieu of Common Shares to investors that so choose, pre-funded warrants (the "Pre-Funded Warrants") to purchase Common Shares, for aggregate gross proceeds of US$100 million (the "Offering"). In connection with the Offering, the Company intends to grant to the underwriters, a 30-day option to purchase up to an additional 15% of the Common Shares issued in the Offering. The Company intends to use the net proceeds from the Offering to fund futu

BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012DEE: 63.3% median reduction in major motor seizures REM sleep improvement in patients with Absence Seizures: mean 90% increase in REM sleep with no change in total sleep durationCompany has initiated preparations for global registrational trials in both DEE and Absence Seizure patientsBright Minds to hold conference call and live webcast at 8AM ET today NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a clinical

6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)

– Conference Call and Live Webcast at 8AM ET – NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a clinical-stage biotechnology company focused on developing highly selective 5-HT receptor agonists for neurological and psychiatric disorders, today announced that it will host a conference call and live webcast at 8:00AM ET on January 6, 2026, to report topline results for the Phase 2 trial of BMB-101 in patients with drug-resistant Absence Seizures and Developmental and Epileptic Encephalopathy. Webcast Information The Bright Minds virtual event will be webcast live and a replay will be available after th

F-X - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

40-F - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that the Company will participate in the following upcoming events:  EVENT:Piper Sandler 37th Annual Healthcare Conference DATE: Wednesday, December 3, 2025 TIME:11:30am ET    EVENT:2025 American Epilepsy Society Annual Meeting – Scientific Exhibit Session DATE:Sunday, December 7, 2025 TIME:2pm – 5pm ET    About Bright Minds Biosciences Bright Minds Biosciences is

6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)